Latest News

In this week's episode, the focus is on the latest example of no progress on reform, the mindset and intransigence it reveals, the repeated pattern, and the early evidence that it would always end this way. Can it be an opportunity? Next week's Budget is upon us, and the discussion focuses on what to look for, that just because it is not in there, does not mean it is not in there, and why gaining any cut-through will be a real challenge.

On 1 July 2026, the Pharmaceutical Benefits Scheme Community Service Obligation will undergo what might be the most profound change since its creation in 2006.

Victoria has become the latest Australian jurisdiction to fund BEXSERO, the meningococcal B vaccine produced by GSK, joining South Australia, Queensland and the Northern Territory in offering state-supported access while a national roll‑out remains off the table.

Lilly Australia is celebrating 150 years of the company's pivotal contribution to developing medicines by partnering with Vivid Sydney to bring ideas about the future of healthcare to the festival program.

Officials will use participation as evidence that the process was inclusive and broadly supported. That claim provides procedural cover for inaction, allowing officials to present incremental adjustments as stakeholder-supported reform. The Delphi studies will be weaponised as a durable rhetorical shield against renewed scrutiny. There are options.

The company has opened applications for the 2026 Moderna Australia Fellowship, a program that will fund and mentor early-career Australian scientists for two years as they pursue mRNA research and innovation.

Scientists at QIMR Berghofer have unveiled an artificial intelligence screening tool that uses advanced spatial biology analysis to help pathologists detect hidden genetic markers of cancer in standard patient tissue samples.

Announced in 2021 and now running into 2027, the review has produced 9 research papers to date, including 6 by the two organisations leading the current Delphi studies. Is the review being restarted as an internal government process?

The Australian company has been chosen to feature in 'Monarchy and Democracy: A History of Leadership', published by the History of Parliament in partnership with St James’s House, to mark a century of royal and parliamentary life.

La Trobe has responded by creating the Research and Engagement for Antimicrobial Resistance and Community Health initiative, known as REACH, to develop new ways to prevent and treat pathogenic bacteria, fungi, and viruses.

International comparisons might matter, but only if we employ them consistently. Why limit international comparisons, and why are officials redoing so much of what was already done by the formal review?

A Johnson & Johnson CAR-T therapy is now funded in Australia, almost exactly three years to the day after Health Minister Mark Butler acknowledged in response to questions about its availability that the country's use of health technology assessment is 'clunky' and responsible for preventable deaths.